FEBO:NASDAQFenbo Holdings Limited Analysis
Data as of 2026-04-02 - not real-time
$1.14
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Fenbo Holdings trades at $1.14, just below its 20‑day SMA (1.154) and well above the 200‑day SMA (0.946), creating a mixed technical picture. The trend is flagged as bullish, yet the MACD histogram is negative and the signal line is bearish, while volume is on a downtrend and 30‑day volatility spikes above 50%, indicating short‑term pressure. Fundamentally, the company is struggling – revenue fell 36% year‑over‑year, margins are deep in the red (gross 15%, operating –8%, profit –16%) and EBITDA is negative, resulting in a trailing EPS of –$0.20. Despite this, valuation multiples are extremely cheap (price‑to‑sales 0.12, price‑to‑book 2.34) and the DCF model suggests a fair value near $24.6, implying a theoretical upside of over 2,000% if the business could turn around. However, the max drawdown of 55% and a negative beta highlight high market sensitivity and historic price weakness.
Given the stark contrast between the ultra‑low pricing and the deteriorating earnings, investors face a classic high‑risk, high‑potential scenario: the stock is dramatically undervalued on paper but requires a substantive operational recovery to justify any upside.
Given the stark contrast between the ultra‑low pricing and the deteriorating earnings, investors face a classic high‑risk, high‑potential scenario: the stock is dramatically undervalued on paper but requires a substantive operational recovery to justify any upside.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Bearish MACD and decreasing volume
- Price below 20‑day SMA
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Extremely low price‑to‑sales and price‑to‑book ratios
- Potential upside if turnaround occurs
- Continued earnings losses and cash‑flow constraints
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF‑derived fair value far exceeds current price
- Undervalued relative to peers on valuation multiples
- Opportunity for strategic restructuring or acquisition
Key Metrics & Analysis
Financial Health
Revenue Growth-36.20%
Profit Margin-16.01%
ROE-34.28%
ROA-10.22%
Debt/Equity61.59
P/B Ratio2.3
Op. Cash Flow$5.5M
Free Cash Flow$20.1M
Industry P/E33.5
Technical Analysis
TrendBullish
RSI48.5
Support$0.91
Resistance$1.30
MA 20$1.15
MA 50$1.13
MA 200$0.95
MACDBearish
VolumeDecreasing
Fear & Greed Index78.8
Valuation
Fair Value$24.62
GradeUndervalued
TypeValue
Risk Assessment
Beta-0.19
Volatility52.37%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.